



Delivering

**SNOMED** CT

**2019 April Business Meeting**



# Enabling Large-Scale Analysis of Electronic Health Records by Standardizing to a Common Data Model

Peter R. Rijnbeek, PhD  
Associate Professor Health Data Science  
Department of Medical Informatics  
Erasmus MC, The Netherlands

---




## The Journey to large-scale analytics

- Introduction to the use of a Common Data Model and Standardized Vocabularies
- Example: Large-scale Patient-Level Prediction
- The European OHDSI Symposium
- The European Health Data and Evidence (EHDEN) Project






# The health data originates from patient journeys






# Each observational database is just an (incomplete) compilation of patient journeys






# Questions asked across the patient journey







# The journey to real-world evidence: a fully reproducible data flow





# Minimum requirements to achieve reproducibility

Desired attribute	Question	Researcher	Data	Analysis	Result
Reproducible	Identical	Different	Identical	Identical	= Identical





- Complete documented specification that fully describes all data manipulations and statistical procedures
- Full analysis code that executes end-to-end (from source to results) without manual intervention




# Current Approach: "One Study – One Script"

"What's the adherence to my drug of interest?"





# Solution: Data Standardization Enables Systematic Research



Analytical Tools


CDM





## How a common data model + common analytics can support reproducibility

Desired attribute	Question	Researcher	Data	Analysis	Result
Reproducible	Identical	Different	Identical	Identical	= Identical



- Use of common data model splits the journey into two segments: 1) data standardization, 2) analysis execution
- ETL specification and source code can be developed and evaluated separately from analysis design
- CDM creates opportunity for re-use of data step and analysis step



## Observational Health Data Sciences and Informatics (OHDSI) mission

To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care





# OHDSI's global research community




- >200 collaborators from 25 different countries
- Experts in informatics, statistics, epidemiology, clinical sciences
- Active participation from academia, government, industry, providers
- Currently records on about 500 million unique patients in >100 databases

<http://ohdsi.org/who-we-are/collaborators/>



# Open Science




## Standardized, transparent workflows






# How OHDSI Works






# Deep information model OMOP CDM Version 6





# Single Concept Reference Table


All vocabularies stacked up in one table



Vocabulary ID




## Ancestry Relationships: Higher-Level Relationships





# Use of SNOMED in the Standardized Vocabularies

- SNOMED is the standard in several domains, e.g. conditions, procedure.
- Powerful Polyhierarchical Structure.






# SNOMED Challenges

- We have to making mappings from many source coding systems to SNOMED in Europe.
  - We want to use SNOMED across the world: how to deal with countries that do not (yet) have a license?
  - We will require SNOMED extensions to accommodate differences in granularity or classification differences.
-




# Example: SNOMED Challenges





# Preparing your data for analysis



OHDSI tools built to help

**WhiteRabbit:** profile your source data

**Rabbit-In-A-Hat:** map your source structure to CDM tables and fields

**ATHENA:** standardized vocabularies for all CDM domains

**Usagi:** map your source codes to CDM vocabulary

**OHDSI Forums:** Public discussions for OMOP CDM Implementers/developers

**CDM:** DDL, index, constraints for Oracle, SQL Server, PostgreSQL; Vocabulary tables with loading scripts

**ACHILLES:** profile your CDM data; review data quality assessment; explore population-level summaries



# ACHILLES Heel Data Curation

## Data Quality Messages

Search:

Show / hide columns

Message Type	Message
ERROR	101-Number of persons by age, with age at first observation period; should not have age < 0, (n=848)
ERROR	103 - Distribution of age at first observation period (count = 1); min value should not be negative
ERROR	114-Number of persons with observation period before year-of-birth; count (n=851) should not be > 0
ERROR	206 - Distribution of age by visit_concept_id (count = 7); min value should not be negative
ERROR	301-Number of providers by specialty concept_id; 224 concepts in data are not in correct vocabulary (Specialty)
ERROR	400-Number of persons with at least one condition occurrence, by condition_concept_id; 115 concepts in data are not in correct vocabulary (SNOMED)
ERROR	406 - Distribution of age by condition_concept_id (count = 753); min value should not be negative



# ATLAS to build, visualize, and analyze cohorts

— People having any of the following: **Add Primary Criteria...**

a condition occurrence of

**Add Criterion...**

Delete

occurrence start is:  2005-01-01 and 2013-12-31

with age  18 and 55

with a gender of:  FEMALE

with observation at least  days prior and  days after index

Limit primary events to:  per person.

## For people matching the Primary Criteria, include:

— People having  of the following criteria: **Add New Criteria...**

with   occurrences of:

**Add Criterion...**

a condition occurrence of

occurring between  days  and  days  index

Delete Criteria

and with   occurrences of:

**Add Criterion...**

a condition occurrence of

occurring between  days  and  days  index


Delete Criteria






# Characterize the cohorts of interest

- «Back
- Refresh
- Truven MDCD (APS) ▾
- Heracles Runner
- Cohort Specific
- Condition
- Condition Eras
- Conditions by Index
- Dashboard
- Data Density
- Death
- Drug Eras
- Drug Exposures
- Drugs by Index
- Heracles Heel

## Matching Population: MiniSentinel replication - warfarin new users



- Drug Exposures
- Drugs by Index
- Heracles Heel
- Measurements
- Observation Periods
- Observations
- Person
- Procedures
- Procedures by Index
- Visits





# What is OHDSI's strategy to deliver reliable evidence?

- **Methodological research**
    - Develop new approaches to observational data analysis
    - Evaluate the performance of new and existing methods
    - Establish empirically-based scientific best practices
  - **Open-source analytics development**
    - Design tools for data transformation and standardization
    - Implement statistical methods for large-scale analytics
    - Build interactive visualization for evidence exploration
  - **Clinical evidence generation**
    - Identify clinically-relevant questions that require real-world evidence
    - Execute research studies by applying scientific best practices through open-source tools across the OHDSI international data network
    - Promote open-science strategies for transparent study design and evidence dissemination
-




# Evidence OHDSI seeks to generate from observational data

- **Clinical characterization**
  - Natural history: Who has diabetes, and who takes metformin?
  - Quality improvement: What proportion of patients with diabetes experience complications?
- **Population-level effect estimation**
  - Safety surveillance: Does metformin cause lactic acidosis?
  - Comparative effectiveness: Does metformin cause lactic acidosis more than glyburide?
- **Patient-level prediction**
  - Precision medicine: Given everything you know about me, now I started using metformin, what is the chance I will get lactic acidosis?
  - Disease interception: Given everything you know about me, what is the chance I will develop diabetes?






# Clinical Characterization: Population-level heterogeneity across systems, and patient-level heterogeneity within systems






# Population-Level Effect Estimation: LEGEND Study

Head-to-head HTN drug comparisons



- Trials: 40
- $N = 102 - [1148] - 33K$



- Comparisons: 10,278
- $N = 3502 - [212K] - 1.9M$



# Journey of Patient-Level Prediction

An example of large-scale analysis enabled by data  
standardization

---



## Clinicians are confronted with prediction questions on a daily basis. What options do they have?

Deny ability to predict at the individual patient level

Quote an overall average to all patients




Utilize knowledge and personal experience

Provide a personalized prediction based on an advanced clinical prediction model



# Problem definition



Among a target population (T), we aim to predict which patients at a defined moment in time ( $t=0$ ) will experience some outcome (O) during a time-at-risk. Prediction is done using only information about the patients in an observation window prior to that moment in time.



## What are the key inputs to a patient-level prediction study?

Input parameter	Design choice
Target cohort (T)	
Outcome cohort (O)	
Time-at-risk	
Model specification -which model(s)? -which parameters? -which covariates?	



# Types of prediction problems in healthcare

Type	Structure	Example
Disease onset and progression	Amongst patients who are newly diagnosed with <b>&lt;insert your favorite disease&gt;</b> , which patients will go on to have <b>&lt;another disease or related complication&gt;</b> within <b>&lt;time horizon from diagnosis&gt;</b> ?	Among newly diagnosed AFib patients, which will go onto to have ischemic stroke in next 3 years?
Treatment choice	Amongst patients with <b>&lt;indicated disease&gt;</b> who are treated with either <b>&lt;treatment 1&gt;</b> or <b>&lt;treatment 2&gt;</b> , which patients were treated with <b>&lt;treatment 1&gt;</b> (on day 0)?	Among AFib patients who took either warfarin or rivaroxaban, which patients got warfarin? (as defined for propensity score model)
Treatment response	Amongst patients who are new users of <b>&lt;insert your favorite chronically-used drug&gt;</b> , which patients will <b>&lt;insert desired effect&gt;</b> in <b>&lt;time window&gt;</b> ?	Which patients with T2DM who start on metformin stay on metformin after 3 years?
Treatment safety	Amongst patients who are new users of <b>&lt;insert your favorite drug&gt;</b> , which patients will experience <b>&lt;insert your favorite known adverse event from the drug profile&gt;</b> within <b>&lt;time horizon following exposure start&gt;</b> ?	Among new users of warfarin, which patients will have GI bleed in 1 year?
Treatment adherence	Amongst patients who are new users of <b>&lt;insert your favorite chronically-used drug&gt;</b> , which patients will achieve <b>&lt;adherence metric threshold&gt;</b> at <b>&lt;time horizon&gt;</b> ?	Which patients with T2DM who start on metformin achieve $\geq 80\%$ proportion of days covered at 1 year?





# Current status of predictive modelling

## Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review

RECEIVED 27 October 2015  
REVISED 25 January 2016  
ACCEPTED 20 February 2016

Benjamin A Goldstein<sup>1,2</sup>, Ann Marie Navar<sup>2,3</sup>, Michael J Pencina<sup>1,2</sup>, John PA Ioannidis<sup>4,5</sup>



### ABSTRACT

**Objective** Electronic health records (EHRs) are an increasingly common data source for clinical risk prediction, presenting both unique analytic opportunities and challenges. We sought to evaluate the current state of EHR based risk prediction modeling through a systematic review of clinical prediction studies using EHR data.

**Methods** We searched PubMed for articles that reported on the use of an EHR to develop a risk prediction model from 2009 to 2014. Articles were extracted by two reviewers, and we abstracted information on study design, use of EHR data, model building, and performance from each publication and supplementary documentation.

**Results** We identified 107 articles from 15 different countries. Studies were generally very large (median sample size = 26 100) and utilized a diverse array of predictors. Most used validation techniques ( $n=94$  of 107) and reported model coefficients for reproducibility ( $n=83$ ). However, studies did not fully leverage the breadth of EHR data, as they uncommonly used longitudinal information ( $n=37$ ) and employed relatively few predictor variables (median = 27 variables). Less than half of the studies were multicenter ( $n=50$ ) and only 26 performed validation across sites. Many studies did not fully address biases of EHR data such as missing data or loss to follow-up. Average c-statistics for different outcomes were: mortality (0.84), clinical prediction (0.83), hospitalization (0.71), and service utilization (0.71).

**Conclusions** EHR data present both opportunities and challenges for clinical risk prediction. There is room for improvement in designing such studies.



## Current status of predictive modelling

- Inadequate internal validation
- Small sets of features
- Incomplete dissemination of model and results
- No transportability assessment
- Impact on clinical decision making unknown




Relatively few prediction models  
are used in clinical practice





# OHDSI Mission for Patient-Level Prediction

OHDSI aims to develop a systematic process to learn and evaluate large-scale patient-level prediction models using observational health data in a data network





# PLP Framework Paper



## Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data

Jenna M Reps , Martijn J Schuemie, Marc A Suchard, Patrick B Ryan, Peter R Rijnbeek

*Journal of the American Medical Informatics Association*, ocy032,

<https://doi.org/10.1093/jamia/ocy032>

**Published:** 27 April 2018 **Article history** ▼

■ Split View

 PDF

“ Cite

 Permissions

 Share ▼

### Abstract

#### Objective

To develop a conceptual prediction model framework containing standardized steps and describe the corresponding open-source software developed to consistently implement the framework across computational environments and observational healthcare databases to enable model sharing and reproducibility.



# Prediction Model Development




**Problem pre-specification.** A study protocol should unambiguously pre-specify the planned analyses.

**Transparency.** Others should be able to reproduce a study in every detail using the provided information. All analysis code should be made available as open source on the OHDSI Github.



# Prediction Model Development





# Prediction Model Development



Age	Gender	Var_1	...	Var_n	Stroke
34	M	1	0	1	1
50	F	0	0	0	1
24	M	0	1	0	0
67	F	1	1	0	0
34	F	0	0	0	0
65	M	1	0	0	1
34	F	0	0	0	0
40	M	0	1	1	0

Data is extracted from the OMOP CDM using the Feature Extraction R-Package.

This allows for specification of the candidate predictors and time windows.




# Prediction Model Development



**Model training** and **Internal validation** is done using a train test split:

1. Person split: examples are assigned randomly to the train or test set, or
2. Time split: a split is made at a moment in time (temporal validation)






# External Validation



**External validation** is performed using data from multiple populations not used for training.





# Dissemination



**Dissemination** of study results should follow the minimum requirements as stated in the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement <sup>1</sup>.

- Internal and external validation
- Sharing of full model details
- Sharing of all analyses code to allow full reproducibility




Website to share protocol, code, models and results for all databases

<sup>1</sup> Moons, KG et al. Ann Intern Med. 2015;162(1):W1-73




# Example Study



Among patients **in 4 different databases**, we aim to develop prediction models to predict which patients at a defined moment in time (**First Pharmaceutically Treated Depression Event**) will experience one out of **22 different outcomes** during a time-at-risk (**1 year**). Prediction is done using **all demographics, conditions, and drug use** data prior to that moment in time.




# Model Discrimination Stroke






# Model Discrimination

Outcomes






# Model Discrimination









# Transportability Assessment

How well do the models perform on other databases?





# Patient-Level Prediction Workgroup




[www.github.com/OHDSI/PatientLevelPrediction](https://github.com/OHDSI/PatientLevelPrediction)

Jenna M Reps, Martijn J Schuemie, Marc A Suchard, Patrick B Ryan, Peter R Rijnbeek; Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data, Journal of the American Medical Informatics Association, Volume 25, Issue 8, 1 August 2018, Pages 969–975, <https://doi.org/10.1093/jamia/ocy032>



**OHDSI**

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS





# First Annual OHDSI Symposium, March 23th 2018





# Meeting Goals Second OHDSI Symposium



- Provide a platform to stimulate community building
  - Demonstrate the OHDSI approach to Reliable and Reproducible Evidence Generation
  - Educate and train the community
-




# First Annual OHDSI Symposium, March 23th 2018






# Breakdown of Participants: Countries






## Breakdown of Participants: Stakeholders





# Relationship with OHDSI





# The Journey From Data to Evidence





# Lightning Talks





# 35 Posters and 8 Software Demos





## 8 Tutorials with 150 participants




- OMOP-CDM and Vocabularies
- Extract Transform Load
- Cohort Building
- Patient-Level Prediction
- Population-Level Effect Estimation





# We collaboratively need to make the next steps!



- Increase the number of data sources in the open network
- Extend the vocabularies for the European market
- Optimize standardized procedures for quality control
- Further improve and extend the analytical toolset
- Build a sustainable eco-system for mapping support, study execution etc.
- Train all our stakeholders





# EHDEN

EUROPEAN HEALTH DATA & EVIDENCE NETWORK

## The European Health Data and Evidence Network (EHDEN) Project

---

**Peter Rijnbeek, PhD**


Associate Professor Health Data Science  
Department of Medical Informatics  
Erasmus MC, The Netherlands





# INNOVATIVE MEDICINES INITIATIVE

[www.imi.europa.eu](http://www.imi.europa.eu)



IMI 1 (2008-2014)  
2 bn € budget  
59 projects

IMI 2 (2014-2024)  
3.3 bn € budget  
More ambitious, more open &  
greater scope



## EHDEN Project Facts

Start date: 1st Nov 2018  
End date: 30th Apr 2024  
Total duration: 66 months



Total budget: 28,917,357€  
IMI2 Funding: 14,105,750€ (7M Harmonization Fund)  
EFPIA contribution: 14,811,607€ (10M Harmonization Fund)



# EHDEN HAD ITS KICK-OFF MEETING IN JANUARY





## EHDEN: VISION AND MISSION



### Vision

The European Health Data & Evidence Network (EHDEN) aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes and care

### Mission

Our mission is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardized to a common data model



# EHDEN CONSORTIUM




## 22 PARTNERS





# GENERATING RELIABLE EVIDENCE USING THE OMOP CDM



EHDEN will build on expertise and tools from prior IMI projects, such as EMIF, and will collaborate intensively with the global OHDSI community.





## BUILDING THE ECO-SYSTEM: PUTTING THE PIECES TOGETHER






## BUILDING THE ECO-SYSTEM: HARMONISATION

The aim is to map 100 million health records across the EU via a common data model (OMOP), supporting research within a federated network, the BD4BO IMI2 programme, and outcomes-based healthcare



**OHDSI**  
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

- Standards development within OHDSI
- Certified & qualified Small to Medium-sized Enterprises (SMEs) in the EU
- Harmonisation fund to support mapping to CDM





# THE EHDEN OPEN CALL PROCESS

EHDEN's Data Source Prioritisation Committee governs the scope of the open calls for data sources.

## Community of data sources



## Open calls

Series of in-project calls across the EU  
Tailored for project objectives and sustainability

## Grant awarding

Grant applications are evaluated via a pre-defined set of criteria  
Data source prioritisation committee, consisting of both internal and external experts, ranks the grant applications




EHDEN Harmonisation fund  
(up to 100 000 € / grant)

Data sources can choose the SME they want to work with from the pool of EHDEN certified SMEs

SMEs performing mappings will be paid by the data sources, via a grant from the harmonisation fund

Payments are milestone based



Mapped data sources are encouraged to be active members of the EHDEN community, participating in research studies.

## Supporting SMEs



## Open calls

Series of in-project calls across the EU  
Focusing on SMEs able to support mapping and sustainability

## Training & Certification

Training and certification will ensure high-quality mapping procedures  
SME certification committee prioritizes SMEs for training and certification

Widespread geographic coverage of Europe by certified SMEs is desired.



# SME CERTIFICATION PROCEDURE: PILOT CALL



## SME call proces overview

### Open call

You will be able to submit applications for the open call for SMEs from the 1st of April until the 30th of April via the EHDEN website.

### Evaluation

Following an eligibilty check, applications will be evaluated by the SME certification committee.



### Training & Certification:

Certification and training of selected SMEs in all necessary competencies.



## Eligibility criteria

The call is open to Small and Medium-sized Enterprises under the official EU definition:

- Less than 250 staff headcount.
- $\leq 50$ m € turnover or  $\leq 43$ m € balance sheet total.
- Legally established as a business and based in an EU member state or H2020 associated country.

For more details, see [bit.ly/EU\\_SME](https://bit.ly/EU_SME)



# SME CERTIFICATION PROCEDURE

## Training

EHDEN's aim is that all selected SMEs as companies will obtain all the necessary competencies to work with a data source within the EHDEN federated network following the established quality standards.

Training topics include, but are not limited to:

- The EHDEN project and its objectives
- OMOP-CDM and the Standardized Vocabularies
- ETL steps and their implementation with OHDSI tools and approaches developed in EHDEN.
- Fundamentals of proper documentation of the ETL process to assure transparency and reproducibility.
- Expertise in the installation and use of the OHDSI Tools for federated data analyses

The course material will be made available through our online learning platform, the EHDEN academy (<https://academy.ehden.eu>).



## Certification

The final step in the certification program is a face-to-face training and assessment.

Once the SME receives the certificate it obtains the following privileges:

- Member of the EHDEN SME Community
- Listed in the Certified SME Catalogue
- Use of the EHDEN Certification Badge


Following certification, SMEs can support and map data sources which have received an EHDEN grant.





## BUILDING THE ECO-SYSTEM: INFRASTRUCTURE

- Build the infrastructure to enable federated studies on an unprecedented scale in Europe
- Leverage and further develop OHDSI and other tools for high quality analyses
- Use Case driven development
- Ensure interoperability on a global level





# THE EHDEN ACADEMY

EHDEN is developing the EHDEN Academy ([academy.ehden.eu](http://academy.ehden.eu)): an online learning platform that will host courses from OHDSI and EHDEN.



It will contain: Video Lectures, Quizzes, SQL Questions, OHDSI-IN-A-BOX VM integration, and more..

There are a number of implicit and explicit conventions that have been adopted in the CDM. Developers of methods that run methods against the CDM need to understand these conventions. The table below shows the most important conventions.

Field name	Purpose	Example
<entity_id	Unique identifiers for <b>entities</b> (row numbers, or IDs imported from source)	person_id 1234567 visit_occurrence_id 7654321 could be a person identifier or an autogenerated number by the CDM builder
<entity_concept_id	Foreign key into the Standard Vocabulary for <b>Standard Concept</b>	condition_concept_id 313217 (SNOMED "Atrial Fibrillation")
<entity_source_concept_id	Foreign key into the Standard Vocabulary for <b>Source Concept</b>	condition_source_concept_id 44821957 (ICD9CM "Atrial Fibrillation")
<entity_source_value	Verbatim information from the source data, <b>not to be used</b> by any standard analytics	condition_source_value 427.31 (ICD9CM "Atrial Fibrillation")
<entity_type_concept_id	Foreign key into the Vocabulary for the <b>origin of the information</b>	condition_type_concept_id 38000199 ("inpatient header - primary")

Which of the following statements is true?

Select one or more:

- a. If we cannot map to a standard code we loose the record
- b. all fields ending with \_concept\_id refer to the VOCABULARY table
- c. an ICD-9 code should be placed in the condition\_source\_value field
- d. a entity\_id value is unique for the domain not for the whole CDM

Check

Question 1

Correct

Marked out of 1.00

Flag question

Edit question

We like to know how many different vocabularies are available in this CDM? Write a query to get that number.

Answer: (penalty regime: 10, 20, ... %)

Reset answer

```
1 |select count(*) from vocabulary
```

Check

Expected	Got
✓ count (*)	count (*) ✓
46	46


Passed all tests! ✓

Next page





## BUILDING THE ECO-SYSTEM: OUTCOMES



- Incorporation of outcome standards (ICHOM)
- Supporting outcomes-based research and medicine
- Demonstrate the additive value of EHDEN through use cases




## BUILDING THE ECO-SYSTEM: ECOSYSTEM



- A trusted federated data network expanding beyond EHDEN project lifetime
- European-wide network of certified SMEs
- Enable new and augmented health services during and after EHDEN
- Stimulate active collaboration within the community
- Sustainability is a responsibility of all stakeholders



# KEY COMPONENTS FOR EHDEN





# WORK PACKAGE STRUCTURE

## WP1: Evidence Workflow Development

Incorporating the use cases for supporting development and validation of the EHDEN socio-technical approach, inclusive of BD4BO projects

## WP4: Technical Implementation

Key priority is socio-technical development of the EHDEN federated framework and relevant services

## WP7: Project Management and Dissemination

Concentrating on intra-project project management, internal communications and external dissemination, and responding to IMI deliverables

## WP2: Outcome Driven Healthcare

Related to all activities specific to e.g. BD4BO projects outcome focus, and ICHOM standards incorporation

## WP5: Data Workflow Implementation & Service Deployment

Development, oversight and evaluation of the ecosystem development from SME qualification/certification to data source engagement, OMOP CDM mapping and evaluation

## WP3: Personalized Medicine

Focusing on the support of outcomes/value based healthcare, inclusive of clinical prediction models, with the incorporation of 'novel' patient data

## WP6: Outreach and Sustainability

Ensuring the development of value propositions for key stakeholders, and developing the sustainable operational model for EHDEN during and post IMI phase





## FINAL REMARKS



EHDEN and OHDSI will collaboratively work on the implementation of an ecosystem for federated analysis in Europe at an unprecedented scale.

We hope that we can further intensify our collaboration with SNOMED to speak the same language. We are convinced this will empower our research community to generate the reliable evidence our patients need!



## NEED MORE INFORMATION?



[enquiries@ehden.eu](mailto:enquiries@ehden.eu)



**OHDSI**  
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

[www.ohdsi.org](http://www.ohdsi.org)



[www.ehden.eu](http://www.ehden.eu)



[@IMI\\_EHDEN](https://twitter.com/IMI_EHDEN)



[IMI\\_EHDEN](https://www.linkedin.com/company/IMI_EHDEN)



[github.com/EHDEN](https://github.com/EHDEN)



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.